Skip to main content
Home
Platform & products
Lead Alzheimer program ReS19-T
Huntington program ReS18-H
Orphan programs
CRO Services
APP-London model
APPxPS1 model
Tau[P301L] model
Tau[P301S] model
APP[V717I]xTau[P301L] model
APP[V717I]xTau[P301S] model
Seed and spread Tauopathy model
About us
People
News
reMYND’s novel Alzheimer program reports excellent brain exposure and safety profile in Phase 1; transitioning into Phase 2a
reMYND’s ReS19-T program, managing calcium homeostasis for Alzheimer’s, has moved to MAD phase after demonstrating strong safety in SAD phase
reMYND identifies novel target and small molecules with potential to halt and reverse disease progression in Huntington’s disease through oral administration
reMYND extends Series B funding to EUR 24 million
reMYND commences first-in-human trial of ReS19-T Alzheimer’s program
reMYND appoints Dr. Lode Debrabandere as Chief Business Officer
reMYND announces publication in Alzheimer’s and Dementia on pivotal role of cytosolic calcium in Alzheimer’s disease
reMYND announces Clinical Advisory Board to support development of Alzheimer’s programme
reMYND and the US NINDS Epilepsy Therapy Screening Program (ETSP) begin collaboration on epilepsy program
Interreg. project "Memories" update
Interreg. project "Memories" holds 2nd annual symposium & new newsletter is available
Approved project ‘Memories’ (‘Herinneringen’ in Dutch): early diagnostics of Alzheimer’s disease (AD)
Partners
Jobs
Research Associate
Contact
201203 - reMYND initieert eerste klinische studie met het ReS19-T Alzheimer programma.pdf
Home
/
201203 - reMYND initieert eerste klinische studie met het ReS19-T Alzheimer programma.pdf
201203 - reMYND initieert eerste klinische studie met het ReS19-T Alzheimer programma.pdf
(194.33 KB)
